SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 2
    Burris HA3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 24032413.
  • 3
    Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23: 35093516.
  • 4
    Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. [abstract]. Eur J Cancer Suppl. 2005; 3: 12. Abstract PS11.
  • 5
    Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004; 22: 14301438.
  • 6
    Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21: 32963302.
  • 7
    Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002; 87: 161167.
  • 8
    Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001; 19: 34473455.
  • 9
    Shapiro J, Marshall J, Karasek P, et al. G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol. 2005; 23(pt 1 of 2): 16S. Abstract 4012.
  • 10
    Miller A, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47: 207217.
  • 11
    Case LD, Kimmick G, Paskett ED, et al. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002; 7: 181187.
  • 12
    Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006; 106: 23372344.
  • 13
    Parmar MKB, Machin D. Survival Analysis: A Practical Approach. Chichester: John Wiley & Sons, Ltd; 1995.
  • 14
    Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998; 317: 13091312.
  • 15
    Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002; 94: 902910.
  • 16
    Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24: 39463952.
  • 17
    Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005; 6: 369376.
  • 18
    Li CP, Chao Y. A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer. J Clin Oncol. 2004; 22: 14S. Abstract 4144.
  • 19
    Wang XY, Ni QX, Jin ML, et al. Gemcitabine (G) or gemcitabine plus cisplatin (GC) as first-line treatment in Chinese patients (pts) with locally advanced (LAPC) and metastatic pancreatic cancer (MPC): a multicenter, randomized, study. Proc Am Soc Clin Oncol. 2002; 21. Abstract 616.
  • 20
    Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol. 2002; 20: 32703275.
  • 21
    Hermann R, Bodoky G, Ruhstaller T, et al. Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative OncologyGroup (CECOG). Proc Am Soc Clin Oncol. 2005; 23: 310s. Abstract LBA4010.
  • 22
    Ohkawa S. Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol. 2004; 22: 14S. Abstract 4131.
  • 23
    Riess H, Helm A, Niedergethmann I, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol. 2005; 23( suppl 16): 1092. Abstract 4009.
  • 24
    Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005; 16: 16391645.
  • 25
    Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006; 95: 587592.
  • 26
    Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006; 24: 44414447.
  • 27
    Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004; 22: 37763783.
  • 28
    Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 19601966.
  • 29
    Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006; 3: CD0002093.
  • 30
    Heinemann V, Hinke A, Bock S, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from combination chemotherapy applied in advanced pancreatic cancer. Ann Oncol. 2006; 17( suppl 9): ix308. Abstract 10730.
  • 31
    Bria E, Carlini P, Cognetti F, Terzoli E, Giannarelli D. Re: survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. [letter]. J Natl Cancer Inst. 2007; 99: 176.
  • 32
    Xie DR, Liang HL, Wang Y, et al. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol. 2006; 12: 69736981.
  • 33
    Bria E, Carlini P, Gelibter A, et al. Current status of targeted agents in advanced pancreatic cancer (APC): a pooled analysis of 2,361 patients (pts) enrolled in six phase III trials. J Clin Oncol. 2006; 24; 18S. Abstract 4126.
  • 34
    Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist. 2005; 10: 565578.
  • 35
    Ko AH, Hwang J, Venook AP, et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005; 93: 195199.
  • 36
    Gelibter A, Malaguti P, Di Cosimo S, et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer. 2005; 104: 12371245.
  • 37
    Rocha Lima CM, Flores AM. Gemcitabine doublets in advanced pancreatic cancer: should we move on? J Clin Oncol. 2006; 24: 327329.
  • 38
    Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). Proc Am Soc Clin Oncol. 2006; 24: 180S. Abstract LBA4004.